$AYTU

AYTU BIOPHARMA, INC

Aytu BioPharma is a pharmaceutical company focused on commercializing prescription medicines for central nervous system conditions. Headquartered in Denver, Colorado, it operates as one business segment and earns money by selling products through third-party wholesalers, distributors and pharmacies, as well as directly to pharmacy customers. Its products are sold primarily in the United States. Aytu’s portfolio includes EXXUA, an extended-release medicine approved for adults with major depressive disorder; Adzenys and Cotempla, extended-release orally disintegrating tablets for attention deficit hyperactivity disorder; and Karbinal ER, an extended-release antihistamine suspension for allergic conditions. The company launched EXXUA in fiscal 2026 and also operates Aytu RxConnect, a patient support program offering access through a network of over 1,000 pharmacies. Aytu uses contract manufacturers to produce its products.

4
1
1

No SEC Form 4 filings for $AYTU in the last 30 days.

See all $AYTU insider activity →
Med

Aytu BioPharma earnings beat by $0.14, revenue topped estimates

Aytu BioPharma (AYTU) reported Q1 EPS of -$0.20, beating estimates by $0.14, with revenue at $14.84M, exceeding expectations of $12.66M. The stock is down 20.18% over 3 months and 8.08% over 12 months. InvestingPro rates its financial health as 'good performance'.

Rosemont to acquire Aytu BioPharma for $2.70 per share

Rosemont Pharmaceuticals will acquire Aytu BioPharma (NASDAQ:AYTU) for $2.70 per share, a 41.1% premium over Aytu's 30-day average. The deal, approved by Aytu's board, is expected to close by late 2026. Aytu focuses on central nervous system disease treatments. Rosemont is backed by private equity firm Inflexion.

Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results Due to the pending merger with Rosemont Pharmaceuticals Holdings, Inc., the Company will not be holding an earnings conference call to discuss its financial results DENVER, CO / Novemb

AYTU sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning AYTU (AYTU BIOPHARMA, INC). Coverage has skewed bullish: 4 bullish, 1 neutral, and 1 bearish.

Recent AYTU coverage spans earnings, financial news and corporate actions.

What's driving AYTU

  • Earnings beat on both EPS and revenue is likely to support the stock versus expectations, though the article provides no guidance or forward catalyst.

    investing.com · Nov 16, 2026

  • Deal terms set a clear floor for AYTU via a cash offer, shifting trading toward spread, tender mechanics, and deal-risk headlines.

    investing.com · Nov 16, 2026

  • Near-term trading should hinge on merger terms and closing risk, with Q1 cash burn and EXXUA commercialization as secondary drivers.

    SEC EDGAR 8-K · Nov 16, 2026

  • Deal terms and premium create near-term upside support, but closing risk and tender participation become the key drivers.

    SEC EDGAR 8-K · Nov 16, 2026

  • Slight target increase suggests modest optimism.

    benzinga.com · Sep 30, 2026

AlphAI scores every news story that mentions AYTU with an AI model for sentiment and relevance, and aggregates insider trades from AYTU BIOPHARMA, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AYTU

Score
$AYTUHighAI 9/10

Rosemont to acquire Aytu BioPharma for $2.70 per share

Rosemont Pharmaceuticals will acquire Aytu BioPharma (NASDAQ:AYTU) for $2.70 per share, a 41.1% premium over Aytu's 30-day average. The deal, approved by Aytu's board, is expected to close by late 2026. Aytu focuses on central nervous system disease treatments. Rosemont is backed by private equity firm Inflexion.

$AYTUHighEarnings

Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results Due to the pending merger with Rosemont Pharmaceuticals Holdings, Inc., the Company will not be holding an earnings conference call to discuss its financial results DENVER, CO / Novemb

$AYTUHighM&A· target · $2.7 · definitive

AYTU BIOPHARMA, INC (AYTU): Entry into a Material Definitive Agreement

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer Agreement with Rosemont Pharmaceuticals provides for all-cash consideration of $2.70 per share Tender offer price represents 41.1% premium to 30-day volume-weighted average price and 51.7% pr

$AYTUMedEarnings

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 mi

AYTU BIOPHARMA, INC (AYTU): Termination of a Material Definitive Agreement

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. aytu20260624c_8k.htm false 0001385818 0001385818 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 23, 2026 Date of Report (Date of earl

Related tickers